Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project

Background: Around 40% of ER+/HER2-breast carcinomas (BC) present mutations in the PIK3CA gene. Assessment of PIK3CA mutational status is required to identify patients eligible for treatment with PI3Kα inhibitors, with alpelisib currently the only approved tyrosine kinase inhibitor in this setting....

Full description

Bibliographic Details
Main Authors: Ana Peixoto, Luís Cirnes, Ana Luísa Carvalho, Maria João Andrade, Maria José Brito, Paula Borralho, Nuno Coimbra, Pedro M. Borralho, Ana Sofia Carneiro, Lisandra Castro, Lurdes Correia, Maria Rita Dionísio, Carlos Faria, Paulo Figueiredo, Ana Gomes, Joana Paixão, Manuela Pinheiro, Hugo Prazeres, Joana Ribeiro, Natália Salgueiro, Fernando C. Schmitt, Fátima Silva, Ana Rita Silvestre, Ana Carla Sousa, Joana Almeida-Tavares, Manuel R. Teixeira, Saudade André, José Carlos Machado
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Molecular Biosciences
Subjects:
advanced breast cancer
ER+/HER2−
PIK3CA mutations
ring trial
validation
molecular pathology
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2023.1082915/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2023.1082915/full

Similar Items